Janus Henderson Group plc 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-12 2:58 pm Sale | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | JANUS HENDERSON GROUP PLC JHG | 32,180 0.000% | -5,059,105 (-99.37%) | Filing |
| 2023-02-10 11:50 am Purchase | 2022-12-31 | 13G | Travere Therapeutics, Inc. TVTX | JANUS HENDERSON GROUP PLC JHG | 5,091,285 7.900% | 1,075,127 (+26.77%) | Filing |
| 2022-02-10 5:22 pm Sale | 2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX | JANUS HENDERSON GROUP PLC JHG | 4,016,158 6.600% | -67,395 (-1.65%) | Filing |
| 2021-02-12 3:48 pm Purchase | 2020-12-31 | 13G | Travere Therapeutics, Inc. TVTX | JANUS HENDERSON GROUP PLC JHG | 4,083,553 8.000% | 4,083,553 (New Position) | Filing |